Venlafaxine Extended Release in the Short-Term Treatment of Depressed and Anxious Primary Care Patients With Multisomatoform Disorder
J Clin Psychiatry 2006;67(1):72-80
© Copyright 2016 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Objective: This pilot study explored the
efficacy and tolerability of extended-release
venlafaxine (venlafaxine ER) in anxious and/or depressed patients with multisomatoform
Method: This 12-week, multicenter,
randomized, double-blind study evaluated adult
primary care outpatients with MSD and comorbid
major depressive disorder, generalized anxiety
disorder, or social anxiety disorder (DSM-IV criteria).
The intent-to-treat population included 112
patients (venlafaxine ER, N=55; placebo, N=57). The
primary efficacy variable was the change in the 15-item Patient Health Questionnaire (PHQ-15)
somatic symptom severity score. Secondary outcomes included the Hamilton Rating Scale
for Depression (HAM-D-17) and for Anxiety (HAM-A), Clinical Global Impressions-Severity of
Illness (CGI-S) and -Improvement (CGI-I) scales, McGill Quality of Life Questionnaire
Physical Symptoms Scale (MQOL-PS), and Medical Outcomes Study Short-Form 36-Item
questionnaire (MOS SF-36). Data were collected from
April 2003 to December 2003.
Results: The decline by week 12 in
PHQ-15 scores was significant (p < .0001) in both
groups; however, the difference between the venlafaxine ER and placebo groups (-8.3 vs. -6.6,
respectively) was not (p = .097). Improvement was greater with venlafaxine ER than placebo on
the PHQ-15 pain subscale (p = .03), SF-36 bodily
pain scale (26.1 vs. 14.5, p = .03), MQOL-PS (-11.7
vs. -6.0, p = .02), HAM-A psychic anxiety subscale (p = .02), SF-36 mental component
summary (p = .03), time to response (54 vs. 71 days,
p = .01), and CGI-I scale (p = .009). Venlafaxine ER
was generally well tolerated.
Conclusion: These results suggest that
venlafaxine ER may be effective in relieving some types of somatic physical symptoms,
particularly pain, in patients with depression and/or